8-K: Xtant Medical Holdings Announces Stock Purchase Agreement and Amendments to Credit Agreements

Xtant Medical Holdings announces a stock purchase agreement where OrbiMed affiliates will sell approximately 73.1 million shares to Nantahala Capital Management and other investors, alongside amendments to its credit agreements.

Summary

• Xtant Medical Holdings, Inc. announced that on April 10, 2025, its majority stockholders, affiliates of OrbiMed Advisors LLC, entered into a Stock Purchase Agreement with Nantahala Capital Management, LLC and other investors.
• The Sellers will sell approximately 73.1 million shares of common stock at a price of $0.42 per share.
• The Company is not a party to the Stock Purchase Agreement.
• Nantahala has agreed to purchase 57.0 million shares, resulting in them holding 49.1% of the issued and outstanding shares.
• The company also entered into a registration rights agreement with the purchasers, agreeing to file a resale registration statement with the SEC within 30 days of closing.
• The company will use commercially reasonable efforts to have the registration statement declared effective within 60 days of closing (90 days if reviewed by the SEC).
• Xtant Medical also entered into amendments to its credit agreements with MidCap Financial Trust and MidCap Funding IV Trust.
• The amendments increase the Common Stock ownership threshold that triggers a Change in Control from 40% to 49.9%.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the sale by OrbiMed could be seen as negative, the investment by Nantahala and the credit agreement amendments provide some stability.

Positives

• Nantahala's increased investment demonstrates confidence in the company's future.
• The registration rights agreement provides liquidity for the new investors.
• Amending the credit agreements avoids triggering a Change in Control, maintaining financial stability.

Negatives

• The sale by OrbiMed affiliates could be perceived negatively by the market.
• The sale price of $0.42 per share may be viewed as low.

Risks

• The closing of the stock purchase agreement is subject to customary closing conditions.
• Delays in the SEC declaring the resale registration statement effective could impact the investors' ability to sell their shares.
• Failure to comply with the registration rights agreement could result in liabilities for the company.

Future Outlook

The closing of the sale of shares is anticipated to occur as soon as reasonably practicable upon completion of all closing mechanics.

Industry Context

The transaction reflects ongoing investment and consolidation activity within the medical device sector, with private equity firms playing a significant role.

Comparison to Industry Standards

• Similar transactions in the medical device industry often involve private equity firms acquiring significant stakes in companies.
• Registration rights agreements are standard practice to provide liquidity to investors in private placements.
• Amendments to credit agreements are common when there are significant changes in ownership structure.

Stakeholder Impact

• Shareholders will see a change in the ownership structure of the company.
• Employees may experience changes as a result of the new ownership.
• Creditors are impacted by the amendment to the credit agreement.

Next Steps

• The company will file a resale registration statement with the SEC within 30 days of the closing date.
• The company will work to have the registration statement declared effective by the SEC.
• The closing of the stock purchase agreement is expected to occur as soon as reasonably practicable.

Key Dates

Keywords

Xtant Medical Holdings, Stock Purchase Agreement, Nantahala Capital Management, OrbiMed Advisors, Registration Rights Agreement, Credit Agreement, Change in Control, Shares, Resale Registration Statement